These two drugs get compared because they are sold to the same man by the same clinic, often on the same intake form. Clinically they have almost nothing to do with each other. Testosterone acts on the gonadal axis and replaces a hormone the testes are not making enough of. Sermorelin acts on the growth hormone axis and asks the pituitary for a hormone that is still there. Different gland, different hormone, different measurement, different regulatory world.
That means “which is better” is usually the wrong question. The one with real support behind it — barely — is whether adding sermorelin to testosterone does anything, and the answer is thinner than the marketing suggests.
At a glance
| Sermorelin | Testosterone (TRT) | |
|---|---|---|
| Axis | Growth hormone — a GHRH analog asking the pituitary to release your own GH, which the liver turns into IGF-1 [1] | Gonadal — replaces the hormone itself, which then suppresses the body’s own production through feedback |
| Approved US products today | None. Two applications, both discontinued [2] | 66 currently-marketed prescription products across 15 brand names and seven routes — injection, transdermal, subcutaneous, oral, nasal, intramuscular, implant [3] |
| How you get it | Compounded to order by a pharmacy; not reviewed by the FDA before it reaches you | Dispensed as a finished, FDA-reviewed product, or compounded by choice |
| Controlled substance | Absent from the federal schedules [4] | Schedule III, listed among anabolic steroids at 21 CFR 1308.13(f)(84), “including its salts, esters and ethers” [4] |
| Human evidence in adults | One placebo-controlled trial, nineteen people, five months [1] | 390 randomized controlled trials indexed for hypogonadism alone [5] |
| What you monitor | IGF-1, as a stand-in for GH you cannot practically measure [1] | Total and free testosterone, plus hematocrit, estradiol and PSA depending on the protocol |
| Studies joining the two | Seven records in total. One review, one retrospective chart review of fourteen men, and five animal papers — three of them on a GHRH antagonist. Zero clinical trials [6] | |
The approval gap is the largest single difference
On September 14, 2026 the FDA’s own product database lists 89 applications containing testosterone, of which 66 products are currently marketed on prescription under fifteen brand names — AndroGel, Depo-Testosterone, Jatenzo, Natesto, Testopel, Xyosted and the rest — across seven routes of administration [3]. Sermorelin has two applications and neither is marketed; both Geref records are discontinued [2].
That is not a statement about which drug works. It is a statement about who has checked. A marketed product carries a label the FDA reviewed, a manufacturer accountable for each batch, and a body of post-marketing surveillance. A compounded one carries a prescription and a pharmacy’s own quality system, which is why the certificate of analysis matters so much more on this side of the comparison.
Being unscheduled is not an advantage
Testosterone is a Schedule III controlled substance. It appears in the federal schedules by name and structure — “testosterone (17β-hydroxyandrost-4-en-3-one)” — in the anabolic steroid list, with a clause covering its salts, esters and ethers, which is what brings cypionate and enanthate in with it [4]. Sermorelin appears nowhere in that part.
Clinics sometimes present that contrast as a reason to prefer sermorelin. It is worth being clear about what it actually means. Scheduling reflects a documented potential for misuse, and it comes with a regulatory apparatus: prescribing records, refill limits, registered handlers. An unscheduled drug has none of that because no rule was written, not because a safety finding cleared it. Growth hormone itself is also absent from those schedules and is still covered by a separate federal statute, which is the wider point the classification question goes through properly.
Does sermorelin raise testosterone?
Nothing published says so, and the trial usually offered as evidence did not measure it. The 1997 placebo-controlled study lists its outcomes plainly: growth hormone, IGF-1, IGF binding proteins 1 and 3, GH-binding protein, lipids, safety bloods, body composition by DXA scan, skin thickness, insulin sensitivity by glucose tolerance test, and a quality-of-life questionnaire [1]. Testosterone is not on that list.
What the questionnaire found was an improvement in libido in the nine men, at P < 0.01, and no change in the ten women. That is a real result and it is the strongest single number in the study — and it is a self-reported score, in nine people, with no hormone measured behind it. Reading it as “sermorelin raised testosterone” adds a mechanism the trial never tested. The full outcome list, with the population attached to each result, keeps those apart.
The one study that looked at both at once
There is exactly one piece of human data joining sermorelin and testosterone therapy: a 2017 retrospective review of records from 105 men already on testosterone who were prescribed a growth hormone secretagogue regimen for lean mass and fat loss. Fourteen met the compliance criteria. Their mean IGF-1 rose from about 160 to about 239 ng/mL over an average of 134 days, at P < 0.0001 [7].
Three things limit what that can support. The regimen was three drugs at once — GHRP-6, GHRP-2 and sermorelin, 100 mcg of each, three times daily — so none of the effect is attributable to sermorelin. The outcome was IGF-1, a laboratory marker rather than anything a patient would notice; no body-composition or symptom result is reported. And fourteen men, selected out of 105 for compliance, in a chart review with no control group, is a signal to investigate rather than a finding to act on.
The 2020 review covering the same territory puts it in almost those words: testosterone “remains the gold standard” for hypogonadism, secretagogues have emerged as a possible adjunct, and “current data on their clinical efficacy largely remain lacking” [6]. Adjunct, not alternative — and an adjunct whose evidence is missing rather than negative.
What the rest of the literature turns out to be
Searching for both drugs together returns seven records in total, and five of them are not about this question at all. Three are studies of a GHRH antagonist shrinking prostate tissue in animal models of benign prostatic hyperplasia — a molecule working in the opposite direction, in rats. One concerns rats made obese by overfeeding. One is a 1988 paper on growth hormone responses in female rats treated neonatally with testosterone propionate [6].
A count alone would suggest seven studies connect these drugs. Two do. And the query that should turn up trials — sermorelin, testosterone, filtered to clinical trials — returns nothing, while the same filter applied to testosterone and hypogonadism returns 390 [5]. The filter works. The silence is on one side only.
How to actually use this
If you are choosing between them for low energy, low drive or a change in body composition, the two are answering different questions, and the first step is finding out which hormone is actually low. A testosterone panel answers one; an IGF-1 level answers the other, and what an IGF-1 result does and does not tell you is worth reading before you order one. Nothing about the sermorelin literature supports using it in place of testosterone in a man with documented hypogonadism.
If you are already on TRT and considering adding sermorelin, you are in the one scenario the published record addresses at all — and it addresses it with fourteen men, three drugs and a lab marker. That is worth knowing before you pay for it, and it belongs on the list of questions you take into the consultation. The comparison that does put sermorelin against something in its own class is sermorelin against growth hormone itself, where the mechanisms genuinely compete.